CN117771364A - 基于抗cd47剂的卵巢癌疗法 - Google Patents
基于抗cd47剂的卵巢癌疗法 Download PDFInfo
- Publication number
- CN117771364A CN117771364A CN202311510416.3A CN202311510416A CN117771364A CN 117771364 A CN117771364 A CN 117771364A CN 202311510416 A CN202311510416 A CN 202311510416A CN 117771364 A CN117771364 A CN 117771364A
- Authority
- CN
- China
- Prior art keywords
- antibody
- dose
- agent
- cancer
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010033128 Ovarian cancer Diseases 0.000 title claims abstract description 59
- 206010061535 Ovarian neoplasm Diseases 0.000 title claims abstract description 41
- 238000011275 oncology therapy Methods 0.000 title description 2
- 238000000034 method Methods 0.000 claims abstract description 144
- 239000003795 chemical substances by application Substances 0.000 claims description 238
- 230000037452 priming Effects 0.000 claims description 89
- 239000002246 antineoplastic agent Substances 0.000 claims description 23
- 229940127089 cytotoxic agent Drugs 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 22
- 229940014144 folate Drugs 0.000 claims description 21
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 21
- 235000019152 folic acid Nutrition 0.000 claims description 21
- 239000011724 folic acid Substances 0.000 claims description 21
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 17
- 239000012661 PARP inhibitor Substances 0.000 claims description 17
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 claims description 17
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 17
- 239000003112 inhibitor Substances 0.000 claims description 17
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 14
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 14
- 239000002525 vasculotropin inhibitor Substances 0.000 claims description 14
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims description 12
- 229940045207 immuno-oncology agent Drugs 0.000 claims description 10
- 239000002584 immunological anticancer agent Substances 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 201000001342 Fallopian tube cancer Diseases 0.000 claims description 5
- 230000000977 initiatory effect Effects 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 claims 4
- 239000000203 mixture Substances 0.000 abstract description 27
- 238000002512 chemotherapy Methods 0.000 abstract description 5
- 206010028980 Neoplasm Diseases 0.000 description 172
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 96
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 96
- 210000004027 cell Anatomy 0.000 description 95
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 description 75
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 description 75
- 201000011510 cancer Diseases 0.000 description 67
- 201000010099 disease Diseases 0.000 description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 34
- 108090000765 processed proteins & peptides Proteins 0.000 description 34
- 230000027455 binding Effects 0.000 description 33
- 238000009739 binding Methods 0.000 description 32
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 32
- 102000004196 processed proteins & peptides Human genes 0.000 description 32
- 238000011287 therapeutic dose Methods 0.000 description 31
- 229920001184 polypeptide Polymers 0.000 description 29
- 238000011282 treatment Methods 0.000 description 26
- 210000001995 reticulocyte Anatomy 0.000 description 23
- 238000001802 infusion Methods 0.000 description 19
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 18
- 229910052697 platinum Inorganic materials 0.000 description 16
- 230000001225 therapeutic effect Effects 0.000 description 16
- 230000003204 osmotic effect Effects 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 15
- 210000003743 erythrocyte Anatomy 0.000 description 14
- 206010057249 Phagocytosis Diseases 0.000 description 13
- 230000008782 phagocytosis Effects 0.000 description 13
- 235000002639 sodium chloride Nutrition 0.000 description 13
- 108060003951 Immunoglobulin Proteins 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 239000000427 antigen Substances 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 230000007423 decrease Effects 0.000 description 12
- 102000018358 immunoglobulin Human genes 0.000 description 12
- 206010027476 Metastases Diseases 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 11
- 230000009401 metastasis Effects 0.000 description 11
- 229960001592 paclitaxel Drugs 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 230000004083 survival effect Effects 0.000 description 11
- 201000009030 Carcinoma Diseases 0.000 description 10
- 239000011230 binding agent Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 10
- 229960005277 gemcitabine Drugs 0.000 description 10
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 10
- 210000001539 phagocyte Anatomy 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 10
- 241000124008 Mammalia Species 0.000 description 9
- 229930012538 Paclitaxel Natural products 0.000 description 9
- 239000002552 dosage form Substances 0.000 description 9
- 210000001165 lymph node Anatomy 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 8
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 230000000903 blocking effect Effects 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 208000007690 Brenner tumor Diseases 0.000 description 7
- 206010073258 Brenner tumour Diseases 0.000 description 7
- 201000000274 Carcinosarcoma Diseases 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 208000027858 endometrioid tumor Diseases 0.000 description 7
- 201000010972 female reproductive endometrioid cancer Diseases 0.000 description 7
- 208000022669 mucinous neoplasm Diseases 0.000 description 7
- 244000052769 pathogen Species 0.000 description 7
- 208000026087 primary peritoneal tumor Diseases 0.000 description 7
- 230000002459 sustained effect Effects 0.000 description 7
- 206010044412 transitional cell carcinoma Diseases 0.000 description 7
- 208000016525 transitional cell neoplasm Diseases 0.000 description 7
- 208000010576 undifferentiated carcinoma Diseases 0.000 description 7
- 101000955067 Homo sapiens WAP four-disulfide core domain protein 2 Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 102100038965 WAP four-disulfide core domain protein 2 Human genes 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 6
- 108020001507 fusion proteins Proteins 0.000 description 6
- 102000037865 fusion proteins Human genes 0.000 description 6
- 238000003384 imaging method Methods 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 238000004806 packaging method and process Methods 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- JNAHVYVRKWKWKQ-CYBMUJFWSA-N veliparib Chemical compound N=1C2=CC=CC(C(N)=O)=C2NC=1[C@@]1(C)CCCN1 JNAHVYVRKWKWKQ-CYBMUJFWSA-N 0.000 description 6
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 5
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 5
- XXPXYPLPSDPERN-UHFFFAOYSA-N Ecteinascidin 743 Natural products COc1cc2C(NCCc2cc1O)C(=O)OCC3N4C(O)C5Cc6cc(C)c(OC)c(O)c6C(C4C(S)c7c(OC(=O)C)c(C)c8OCOc8c37)N5C XXPXYPLPSDPERN-UHFFFAOYSA-N 0.000 description 5
- 102000001554 Hemoglobins Human genes 0.000 description 5
- 108010054147 Hemoglobins Proteins 0.000 description 5
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 5
- 239000002138 L01XE21 - Regorafenib Substances 0.000 description 5
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 5
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 5
- 229940123237 Taxane Drugs 0.000 description 5
- 108010081667 aflibercept Proteins 0.000 description 5
- 229960002833 aflibercept Drugs 0.000 description 5
- 229960000473 altretamine Drugs 0.000 description 5
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 5
- 229960000397 bevacizumab Drugs 0.000 description 5
- 229960004117 capecitabine Drugs 0.000 description 5
- 229960004562 carboplatin Drugs 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- HWGQMRYQVZSGDQ-HZPDHXFCSA-N chembl3137320 Chemical compound CN1N=CN=C1[C@H]([C@H](N1)C=2C=CC(F)=CC=2)C2=NNC(=O)C3=C2C1=CC(F)=C3 HWGQMRYQVZSGDQ-HZPDHXFCSA-N 0.000 description 5
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 5
- 229960004316 cisplatin Drugs 0.000 description 5
- 229960004397 cyclophosphamide Drugs 0.000 description 5
- 229960003668 docetaxel Drugs 0.000 description 5
- 229960004679 doxorubicin Drugs 0.000 description 5
- 102000006815 folate receptor Human genes 0.000 description 5
- 108020005243 folate receptor Proteins 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 5
- 229960001101 ifosfamide Drugs 0.000 description 5
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 229960004768 irinotecan Drugs 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229960001924 melphalan Drugs 0.000 description 5
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 description 5
- 229950011068 niraparib Drugs 0.000 description 5
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 description 5
- 229960000572 olaparib Drugs 0.000 description 5
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 5
- 229960005079 pemetrexed Drugs 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 229960004836 regorafenib Drugs 0.000 description 5
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 5
- HMABYWSNWIZPAG-UHFFFAOYSA-N rucaparib Chemical group C1=CC(CNC)=CC=C1C(N1)=C2CCNC(=O)C3=C2C1=CC(F)=C3 HMABYWSNWIZPAG-UHFFFAOYSA-N 0.000 description 5
- 229950004707 rucaparib Drugs 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 229960000303 topotecan Drugs 0.000 description 5
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 5
- PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 description 5
- 229960000977 trabectedin Drugs 0.000 description 5
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 5
- 229960002066 vinorelbine Drugs 0.000 description 5
- 230000003442 weekly effect Effects 0.000 description 5
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 4
- 108010074604 Epoetin Alfa Proteins 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 4
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 4
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 4
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 206010061309 Neoplasm progression Diseases 0.000 description 4
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 208000007502 anemia Diseases 0.000 description 4
- 239000003173 antianemic agent Substances 0.000 description 4
- 238000003782 apoptosis assay Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 229940125367 erythropoiesis stimulating agent Drugs 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 230000003449 preventive effect Effects 0.000 description 4
- 230000005522 programmed cell death Effects 0.000 description 4
- 238000012292 receptor occupancy assay Methods 0.000 description 4
- 238000009738 saturating Methods 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 4
- 230000005751 tumor progression Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 108090000394 Erythropoietin Proteins 0.000 description 3
- 102000003951 Erythropoietin Human genes 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000002269 analeptic agent Substances 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229940105423 erythropoietin Drugs 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- -1 nano-nab-paclitaxel Chemical compound 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000007910 systemic administration Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 108010019673 Darbepoetin alfa Proteins 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 2
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 206010064390 Tumour invasion Diseases 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003095 anti-phagocytic effect Effects 0.000 description 2
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000009400 cancer invasion Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 238000011194 good manufacturing practice Methods 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 229940124452 immunizing agent Drugs 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000002601 intratumoral effect Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 208000016848 malignant germ cell tumor Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000011518 platinum-based chemotherapy Methods 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229940029359 procrit Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 208000028467 sex cord-stromal tumor Diseases 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 229950011257 veliparib Drugs 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 102000000412 Annexin Human genes 0.000 description 1
- 108050008874 Annexin Proteins 0.000 description 1
- 241001289435 Astragalus brachycalyx Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 239000012275 CTLA-4 inhibitor Substances 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241001125671 Eretmochelys imbricata Species 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 235000002917 Fraxinus ornus Nutrition 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 241001112691 Goatpox virus Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 241000921938 Mule deerpox virus Species 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000700562 Myxoma virus Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 239000012270 PD-1 inhibitor Substances 0.000 description 1
- 239000012668 PD-1-inhibitor Substances 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 241000700665 Sheeppox virus Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000700565 Swinepox virus Species 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000006593 Urologic Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 229940115115 aranesp Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 208000013404 behavioral symptom Diseases 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 1
- 229960005029 darbepoetin alfa Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 229960003388 epoetin alfa Drugs 0.000 description 1
- 229940089118 epogen Drugs 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 231100000324 minimal toxicity Toxicity 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000036438 mutation frequency Effects 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000000683 nonmetastatic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940121655 pd-1 inhibitor Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762573835P | 2017-10-18 | 2017-10-18 | |
| US62/573,835 | 2017-10-18 | ||
| CN201880068424.8A CN111247172B (zh) | 2017-10-18 | 2018-10-18 | 基于抗cd47剂的卵巢癌疗法 |
| PCT/US2018/056441 WO2019079548A1 (en) | 2017-10-18 | 2018-10-18 | OVARIAN CANCER THERAPY BASED ON ANTI-CD47 AGENT |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880068424.8A Division CN111247172B (zh) | 2017-10-18 | 2018-10-18 | 基于抗cd47剂的卵巢癌疗法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117771364A true CN117771364A (zh) | 2024-03-29 |
Family
ID=64267915
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311510416.3A Pending CN117771364A (zh) | 2017-10-18 | 2018-10-18 | 基于抗cd47剂的卵巢癌疗法 |
| CN201880068424.8A Active CN111247172B (zh) | 2017-10-18 | 2018-10-18 | 基于抗cd47剂的卵巢癌疗法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880068424.8A Active CN111247172B (zh) | 2017-10-18 | 2018-10-18 | 基于抗cd47剂的卵巢癌疗法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11802153B2 (enExample) |
| EP (2) | EP4177270B1 (enExample) |
| JP (2) | JP7308191B2 (enExample) |
| KR (1) | KR102776457B1 (enExample) |
| CN (2) | CN117771364A (enExample) |
| AU (1) | AU2018351006B2 (enExample) |
| CA (1) | CA3078253A1 (enExample) |
| ES (2) | ES2989007T3 (enExample) |
| PL (2) | PL3697817T3 (enExample) |
| PT (2) | PT4177270T (enExample) |
| SI (2) | SI3697817T1 (enExample) |
| WO (1) | WO2019079548A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2796378T3 (es) | 2016-01-11 | 2020-11-26 | Forty Seven Inc | Anticuerpos monoclonales anti-cd47 humanizados, de ratón o químicos |
| US11802153B2 (en) | 2017-10-18 | 2023-10-31 | Forty Seven, Inc. | Anti-CD47 agent-based ovarian cancer therapy |
| EP4129336B1 (en) | 2018-02-12 | 2025-05-07 | Forty Seven, LLC | Anti-cd47 agent-based treatment of cd20-positive cancer |
| CA3111323A1 (en) | 2018-09-04 | 2020-03-12 | Trillium Therapeutics Inc. | Cd47 blockade with parp inhibition for disease treatment |
| AU2020410410A1 (en) | 2019-12-17 | 2022-06-09 | Pfizer Inc. | Antibodies specific for CD47, PD-L1, and uses thereof |
| CN115361971A (zh) * | 2020-04-06 | 2022-11-18 | 里兰斯坦福初级大学理事会 | 抗体制剂 |
| JP2023530499A (ja) * | 2020-06-22 | 2023-07-18 | モルフォシス・アーゲー | 抗ＣＤ１９抗体及びＳＩＲＰα－ＣＤ４７自然免疫チェックポイントを遮断するポリペプチドを含む抗腫瘍組み合わせ療法 |
| WO2022171121A1 (zh) * | 2021-02-10 | 2022-08-18 | 同润生物医药(上海)有限公司 | 治疗肿瘤的方法和组合 |
| CA3193664A1 (en) * | 2021-04-14 | 2022-10-20 | Akeso Biopharma, Inc. | Anti-cd47 monoclonal antibody and use thereof |
| KR20240019111A (ko) * | 2021-06-10 | 2024-02-14 | 오노 야꾸힝 고교 가부시키가이샤 | Cd47 저해 물질, 면역 체크포인트 저해 물질 및 표준 요법의 병용에 의한 암 치료법 |
| CN115245516A (zh) * | 2021-12-31 | 2022-10-28 | 郑州大学第一附属医院 | 一种抗卵巢癌肿瘤药物联用方法、体外和体内验证方法 |
| US20250228938A1 (en) * | 2022-03-08 | 2025-07-17 | Whitehead Institute For Biomedical Research | The combination of macrophage-directed immunotherapy and targeted agents for treatment of cancer |
| TWI876305B (zh) * | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2735144T3 (es) | 2008-01-15 | 2019-12-16 | Univ Leland Stanford Junior | Métodos para manipular fagocitosis mediada por CD47 |
| US20160095939A1 (en) | 2014-10-07 | 2016-04-07 | Immunomedics, Inc. | Neoadjuvant use of antibody-drug conjugates |
| US8758750B2 (en) | 2009-09-15 | 2014-06-24 | The Board Of Trustees Of The Leland Stanford Junior University | Synergistic anti-CD47 therapy for hematologic cancers |
| WO2011041453A1 (en) | 2009-09-29 | 2011-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Isolation and use of melanoma cancer stem cells |
| JP6166177B2 (ja) | 2010-05-14 | 2017-07-19 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Ｃｄ４７に対するヒト化及びキメラモノクローナル抗体 |
| WO2012088309A1 (en) | 2010-12-21 | 2012-06-28 | The Board Of Trustees Of The Leland Stanford Junior University | Therapeutic and diagnostic methods for manipulating phagocytosis through calreticulin and low density lipoprotein-related receptor |
| SMT202000689T1 (it) | 2012-01-17 | 2021-01-05 | Univ Leland Stanford Junior | Reagenti per sirp-alfa ad alta affinita' |
| BR112015013431A2 (pt) * | 2012-12-12 | 2017-11-14 | Vasculox Inc | anticorpos monoclonais ou respectivos fragmentos ligantes de antígenos, composição farmacêutica, e usos de anticorpo monoclonal ou respectivo fragmento ligante de antígenos |
| ES2728066T3 (es) | 2013-03-15 | 2019-10-22 | Univ Leland Stanford Junior | Métodos para la obtención de dosis terapéuticamente eficaces de agentes anti-CD47 |
| JP6843611B2 (ja) | 2013-04-29 | 2021-03-17 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 免疫を強化する抗ｃｄ４７因子の使用 |
| US9945870B2 (en) | 2013-05-17 | 2018-04-17 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for determining responsiveness to an anti-CD47 agent |
| EP3116544A4 (en) | 2014-03-11 | 2017-08-23 | The Board of Trustees of the Leland Stanford Junior University | Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies |
| WO2016023001A1 (en) | 2014-08-08 | 2016-02-11 | The Board Of Trustees Of The Leland Stanford Junior University | Multispecific high affinity pd-1 agents and methods of use |
| ES2819451T3 (es) | 2014-08-08 | 2021-04-16 | Univ Leland Stanford Junior | Agentes PD-1 de alta afinidad y procedimientos de uso |
| EP3209769B1 (en) | 2014-10-24 | 2020-08-05 | The Board of Trustees of the Leland Stanford Junior University | Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| AU2016209268B2 (en) | 2015-01-21 | 2021-04-29 | The Board Of Trustees Of The Leland Stanford Junior University | Macrophages eat cancer cells using their own calreticulin as a guide |
| US10358472B2 (en) | 2015-05-06 | 2019-07-23 | The Board Of Trustees Of The Leland Stanford Junior University | High affinity CD47 analogs |
| US20180147257A1 (en) | 2015-05-22 | 2018-05-31 | The Board Of Trustees Of The Leland Stanford Junior University | Btn3a ectodomain proteins and methods of use |
| WO2017019767A1 (en) | 2015-07-27 | 2017-02-02 | Myosotis, Llc | Inhibition of CXCL12 in Cancer Immunotherapy |
| SI3341015T2 (sl) | 2015-08-26 | 2024-03-29 | The Board Of Trustees Of The Leland Stanford, Junior University | Izboljšana deplecija ciljanih celic z blokado CD47 in imunostimulatornim agonistom |
| WO2017049251A2 (en) * | 2015-09-18 | 2017-03-23 | Tioma Therapeutics, Inc. | Therapeutic cd47 antibodies |
| US10344094B2 (en) * | 2015-12-11 | 2019-07-09 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of cancer with dual targeting of CD47 and EGFR |
| BR112018013094A2 (pt) | 2015-12-28 | 2018-12-11 | Merck Patent Gmbh | combinação de inibidor de hdac e anticorpo de anti-pd-l1 para o tratamento de câncer ovariano |
| ES2796378T3 (es) | 2016-01-11 | 2020-11-26 | Forty Seven Inc | Anticuerpos monoclonales anti-cd47 humanizados, de ratón o químicos |
| CN109071676A (zh) * | 2016-01-21 | 2018-12-21 | 小利兰·斯坦福大学托管委员会 | 使用免疫调节剂的组合的癌症治疗 |
| PL3442578T3 (pl) | 2016-04-15 | 2022-06-20 | The Board Of Trustees Of The Leland Stanford Junior University | Sposoby określania i osiągania terapeutycznie skutecznych dawek środków anty-cd47 w leczeniu nowotworów |
| US10611842B2 (en) | 2016-08-03 | 2020-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Disrupting FC receptor engagement on macrophages enhances efficacy of anti-SIRPα antibody therapy |
| WO2018031419A1 (en) | 2016-08-12 | 2018-02-15 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for enhancing immunogenic cross-presentation of tumor antigens |
| WO2018081448A1 (en) | 2016-10-26 | 2018-05-03 | The Board Of Trustees Of The Leland Stanford Junior University | Modified immunoglobulin hinge regions to reduce hemagglutination |
| WO2018165015A1 (en) | 2017-03-09 | 2018-09-13 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of pediatric brain tumors with targeting of cd47 pathway |
| US11802153B2 (en) | 2017-10-18 | 2023-10-31 | Forty Seven, Inc. | Anti-CD47 agent-based ovarian cancer therapy |
| EP4194470A1 (en) | 2017-10-18 | 2023-06-14 | Forty Seven, Inc. | Treatment of ovarian cancer with anti-cd47 and anti-pd-l1 |
| EP3807319A4 (en) | 2018-06-13 | 2022-05-25 | The Board of Trustees of the Leland Stanford Junior University | Compositions and methods for inducing phagocytosis |
| WO2020068431A1 (en) | 2018-09-28 | 2020-04-02 | The Board Of Trustees Of The Leland Stanford Junior University | Analysis of polymorphisms in sirp-alpha for evaluating response to immunotherapy |
| WO2020160285A1 (en) | 2019-02-01 | 2020-08-06 | The Board Of Trustees Of The Leland Stanford Junior University | SIRPα EXPRESSION ON T CELLS IS A BIOMARKER FOR FUNCTIONAL T CELLS DURING EXHAUSTION |
| WO2020163692A1 (en) | 2019-02-08 | 2020-08-13 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of cutaneous t cell lymphoma with targeting of cd47 pathway |
-
2018
- 2018-10-18 US US16/756,673 patent/US11802153B2/en active Active
- 2018-10-18 CA CA3078253A patent/CA3078253A1/en active Pending
- 2018-10-18 WO PCT/US2018/056441 patent/WO2019079548A1/en not_active Ceased
- 2018-10-18 KR KR1020207014145A patent/KR102776457B1/ko active Active
- 2018-10-18 SI SI201830808T patent/SI3697817T1/sl unknown
- 2018-10-18 EP EP22199536.8A patent/EP4177270B1/en active Active
- 2018-10-18 JP JP2020522016A patent/JP7308191B2/ja active Active
- 2018-10-18 PT PT221995368T patent/PT4177270T/pt unknown
- 2018-10-18 PL PL18800381.8T patent/PL3697817T3/pl unknown
- 2018-10-18 ES ES22199536T patent/ES2989007T3/es active Active
- 2018-10-18 AU AU2018351006A patent/AU2018351006B2/en active Active
- 2018-10-18 CN CN202311510416.3A patent/CN117771364A/zh active Pending
- 2018-10-18 PT PT188003818T patent/PT3697817T/pt unknown
- 2018-10-18 ES ES18800381T patent/ES2932286T3/es active Active
- 2018-10-18 CN CN201880068424.8A patent/CN111247172B/zh active Active
- 2018-10-18 SI SI201831145T patent/SI4177270T1/sl unknown
- 2018-10-18 EP EP18800381.8A patent/EP3697817B1/en active Active
- 2018-10-18 PL PL22199536.8T patent/PL4177270T3/pl unknown
-
2022
- 2022-11-22 JP JP2022186406A patent/JP2023018062A/ja active Pending
-
2023
- 2023-09-27 US US18/373,655 patent/US20240150461A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20200283520A1 (en) | 2020-09-10 |
| ES2932286T3 (es) | 2023-01-17 |
| CA3078253A1 (en) | 2019-04-25 |
| JP2023018062A (ja) | 2023-02-07 |
| KR20200068730A (ko) | 2020-06-15 |
| US11802153B2 (en) | 2023-10-31 |
| PT4177270T (pt) | 2024-10-23 |
| EP4177270B1 (en) | 2024-07-31 |
| JP7308191B2 (ja) | 2023-07-13 |
| CN111247172B (zh) | 2023-11-14 |
| PT3697817T (pt) | 2023-01-02 |
| SI3697817T1 (sl) | 2023-01-31 |
| PL3697817T3 (pl) | 2023-01-23 |
| AU2018351006A1 (en) | 2020-05-07 |
| EP3697817B1 (en) | 2022-10-05 |
| ES2989007T3 (es) | 2024-11-25 |
| EP3697817A1 (en) | 2020-08-26 |
| AU2018351006B2 (en) | 2024-08-29 |
| KR102776457B1 (ko) | 2025-03-06 |
| CN111247172A (zh) | 2020-06-05 |
| US20240150461A1 (en) | 2024-05-09 |
| PL4177270T3 (pl) | 2024-11-18 |
| JP2021500349A (ja) | 2021-01-07 |
| SI4177270T1 (sl) | 2024-10-30 |
| WO2019079548A1 (en) | 2019-04-25 |
| EP4177270A1 (en) | 2023-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240150461A1 (en) | Anti-cd47 agent-based ovarian cancer therapy | |
| US20240218077A1 (en) | Anti-cd47 agent-based treatment of cd20-positive cancer | |
| US20210047416A1 (en) | Treatment of ovarian cancer with anti-cd47 and anti-pd-l1 | |
| HK40092156A (en) | Anti-cd47 agent-based ovarian cancer therapy | |
| HK40092156B (en) | Anti-cd47 agent-based ovarian cancer therapy | |
| HK40029255B (zh) | 基於抗cd47剂的卵巢癌疗法 | |
| HK40029255A (en) | Anti-cd47 agent-based ovarian cancer therapy | |
| HK40036030B (en) | Anti-cd47 agent-based ovarian cancer therapy | |
| HK40036030A (en) | Anti-cd47 agent-based ovarian cancer therapy | |
| WO2025240343A1 (en) | Tgf-beta inhibitors for treating cancer | |
| HK40086849A (en) | Anti-cd47 agent-based treatment of cd20-positive cancer | |
| HK40029258A (en) | Anti-cancer regimen using anti-cd47 and anti-cd20 antibodies | |
| HK40084229A (en) | Treatment of cancer with dual targeting of cd47 and egfr | |
| HK40043124B (en) | Anti-cancer regimen using anti-cd47 and anti-cd20 antibodies | |
| HK40043124A (en) | Anti-cancer regimen using anti-cd47 and anti-cd20 antibodies | |
| HK1259512A1 (en) | Treatment of cancer with dual targeting of cd47 and egfr |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |